Delcath Systems (NASDAQ:DCTH – Get Free Report) and INVO Bioscience (NASDAQ:INVO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.
Profitability
This table compares Delcath Systems and INVO Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Delcath Systems | -26.38% | -29.44% | -20.75% |
| INVO Bioscience | -122.79% | N/A | -36.94% |
Valuation and Earnings
This table compares Delcath Systems and INVO Bioscience”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Delcath Systems | $37.21 million | 13.25 | -$26.39 million | ($0.50) | -28.32 |
| INVO Bioscience | $5.77 million | 0.83 | -$8.03 million | N/A | N/A |
INVO Bioscience has lower revenue, but higher earnings than Delcath Systems.
Risk and Volatility
Delcath Systems has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, INVO Bioscience has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500.
Insider & Institutional Ownership
61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 12.0% of INVO Bioscience shares are held by institutional investors. 17.4% of Delcath Systems shares are held by company insiders. Comparatively, 3.5% of INVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations for Delcath Systems and INVO Bioscience, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Delcath Systems | 0 | 0 | 4 | 0 | 3.00 |
| INVO Bioscience | 0 | 0 | 0 | 0 | 0.00 |
Delcath Systems presently has a consensus price target of $24.00, suggesting a potential upside of 69.49%. Given Delcath Systems’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Delcath Systems is more favorable than INVO Bioscience.
Summary
Delcath Systems beats INVO Bioscience on 9 of the 12 factors compared between the two stocks.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
About INVO Bioscience
INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.
